Is Krishna Institute of Medical Sciences (KIMS) overvalued or fairly valued?

MarketChacha shows Krishna Institute of Medical Sciences's valuation in context — a forward P/E of about 48.2, a price-to-book of about 14.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Krishna Institute of Medical Sciences's revenue?

Krishna Institute of Medical Sciences reported revenue of ₹1,702 Cr for FY2026, with net profit of ₹261 Cr, per official filings.

What is the share price of Krishna Institute of Medical Sciences (KIMS)?

Krishna Institute of Medical Sciences last traded at ₹813.05 (-0.8% on the day), as of 8/11/2026 — a delayed quote shown for education, not investment advice.

Krishna Institute of Medical Sciences

KIMS · NSE · Healthcare · India

Snapshot

TickerKIMS

ExchangeNSE

SectorHealthcare

IndustryMedical Care Facilities

CountryIndia

HeadquartersSecunderabad, India

Websitewww.kimshospitals.com

Filings tracked9

About Krishna Institute of Medical Sciences

Krishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand in India. The company offers arthroscopy and shoulder, cardiology, cardiothoracic and cardiovascular, organ transplant, medical and surgical gastroenterology, hepatology, orthopaedic, neurology, neurosurgery, nephrology, urology, oncology, pediatric, neonatology, obstetrics and gynaecology, fertility, dental science, emergency and critical care, vascular, rehabilitation and physiotherapy services. It also provides pulmonology, diagnostic and imaging, ophthalmology, ENT, rheumatology and clinical immunology, internal medicine, interventional radiology, diabetology, endocrinology, general surgery, infectious disease, dermatology, thoracic surgery, psychiatry, plastic and reconstructive surgery, transfusion medicine, clinical psychology, anesthesiology, and tele medicine services. In addition, the company operates clinical immunology allergy, bone marrow transplantation, hair transplant, andrology, fertility, alzheimer, arthroscopy, bone and joint, breast, dialysis, female urology, IUI, IVF, joint replacement, kidney health and transplant, ICU, spine, stroke, TAVR/TAVI, hepatobiliary surgery, and trauma centers, as well as pain and wellness clinics. Further, it provides bariatric, thoracic, oral maxillofacial, and endovascular surgery services. Krishna Institute of Medical Sciences Limited was incorporated in 1973 and is based in Secunderabad, India.

Who owns it

Promoters41.7%
Institutions39.7%
Public & other18.6%

76 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend15.3% → 15.3%

Margin has held broadly steady over the period — stable profitability.

Growth qualityrev -8% · PAT -8%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (BSE (official results filing)). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹1,264 Cr · EPS 1.97

Est. earnings growth +48.1%

Next fiscal year

Rev ₹6,190 Cr · EPS 16.86

Est. earnings growth +63.2%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: BSE (official results filing)

Annual

Quarterly · last 5

Revenue (FY2026)

₹1,702 Cr

Net margin

15.3%

Revenue CAGR (3y)

-8.2%

Profit CAGR (3y)

-8.1%

EPS (FY2026)

6.52

Net profit (FY2026)

₹261 Cr

Ask MarketChacha about KIMS

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin
FY2026	₹1,702 Cr	₹261 Cr	6.52	15.3%
FY2025	₹3,035 Cr	₹385 Cr	—	12.7%
FY2024	₹2,498 Cr	₹310 Cr	—	12.4%
FY2023	₹2,198 Cr	₹336 Cr	—	15.3%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	₹484 Cr	₹67 Cr	1.66	13.8%
2026Q1	₹456 Cr	₹66 Cr	1.65	14.4%
2025Q4	₹442 Cr	₹73 Cr	1.81	16.4%
2025Q3	₹961 Cr	₹67 Cr	—	7.0%
2025Q2	₹872 Cr	₹79 Cr	—	9.0%

Figures as reported, in ₹ (crore). Source: BSE (official results filing).

Filings & announcements

2026

Earnings Call Transcript
Transcript of earnings conference call with investors held on 04 August, 2026
BSE8/8/2026
Letter To Shareholders Regarding Annual Report
Letter to Shareholders Regarding Annual Report
BSE8/5/2026
Business Responsibility and Sustainability Reporting (BRSR)
BRSR for the FY 2025-26
BSE8/5/2026
Reg. 34 (1) Annual Report.
24th Annual Report for the FY 2025-26
BSE8/5/2026
24Th Annual General Meeting Of The Company Scheduled To Be Held On 27Th August 2026
24th Annual General Meeting Scheduled to be held on 27th August, 2026
BSE8/5/2026material
Monitoring Agency Report
Monitoring Agency Report for the Quarter ended June 30, 2026.
BSE8/3/2026
Statement Of Deviation
Statement of Deviation for quarter ended June 30, 2026.
BSE8/3/2026
Financial Results For Q1 2026-27
Financial Results for Q1 2026-27
BSE8/3/2026
Board Meeting Outcome for Outcome Of The Board Meeting Held On 03Rd August, 2026
Outcome of the Board meeting held on 03rd August 2026
BSE8/3/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.